Kyverna Therapeutics Q3 2024 Earnings Report

Kyverna Therapeutics EPS Results

• Actual EPS: -$0.80
• Consensus EPS: -$0.81
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Kyverna Therapeutics Revenue Results

• Actual Revenue: $0.01 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Kyverna Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/13/2024
• Time: After Market Closes
• Conference Call Date: Wednesday, November 13, 2024
• Conference Call Time: 4:00PM ET

Kyverna Therapeutics (NASDAQ:KYTX) is a clinical-stage biotechnology company focused on the development of engineered T cell therapies for cancer. Leveraging advancements in gene editing and cell therapy, Kyverna is building an off-the-shelf portfolio of allogeneic chimeric antigen receptor (CAR) T and T cell receptor (TCR)-based treatments. The company’s proprietary Nyx platform enables precise, multiplexed genetic modifications designed to enhance the safety, potency and persistence of therapeutic T cells without the need for patient-specific manufacturing.

Kyverna’s lead program, KYX101, is an allogeneic CAR T cell therapy targeting CD19 for the treatment of relapsed or refractory B-cell malignancies and is currently in early-phase clinical evaluation. In addition, the company is advancing KYX102, an allogeneic CAR T product candidate directed against B cell maturation antigen (BCMA) for multiple myeloma, as well as TCR-based constructs aimed at solid tumor antigens. Preclinical data have demonstrated encouraging anti-tumor activity and the potential to address challenges associated with immune evasion and antigen heterogeneity.

Founded in 2023 as a spin-out rooted in pioneering gene-editing research, Kyverna is headquartered in Cambridge, Massachusetts, with research and process development operations in North America and Europe. The company collaborates with leading academic centers and contract development and manufacturing organizations to streamline the translation of its cell therapy candidates into clinical studies. Kyverna has established strategic partnerships to support scalable manufacturing and to facilitate regulatory filings across multiple jurisdictions.

Kyverna’s leadership team is composed of industry veterans drawn from top cell therapy and gene-editing organizations. Chief Executive Officer Gregory Schiffman brings more than two decades of biopharmaceutical experience, while Chief Scientific Officer Dr. Melissa Granger leads the company’s translational research initiatives. Together, the team is dedicated to advancing next-generation allogeneic cell therapies that have the potential to broaden patient access to life-saving treatments.